PureTech Health (PRTC) H1 2024 earnings summary

Executive summary

• Completed enrollment in phase 2b trial of LYT-100 (Deupirfenidone) for IPF, with top-line results expected by year-end 2024.

• Monetized Karuna stake, receiving $293M from BMS acquisition and eligible for up to $400M in milestones and future royalties.

• Returned $150M to shareholders via $100M tender offer and $50M buyback since May 2022.

• Launched Seaport Therapeutics with $100M Series A; advanced LYT-200 via Gallop Oncology.

• Strong balance sheet with $500.4M in cash and investments at June 30, 2024, providing at least three years of operational runway.

Financial highlights

• Cash, cash equivalents, and short-term investments at June 30, 2024: $500.4M, up from $327.1M at Dec 31, 2023.

• Operating expenses for H1 2024: $66.7M, down from $79.3M in H1 2023.

• Net loss attributable to owners: $41.8M for H1 2024, compared to $25.0M in H1 2023.

• Total revenue: $0.3M for H1 2024, down 91% year-over-year due to deconsolidation of Vedanta and completion of Entrega revenue agreement.

• R&D expenses: $38.9M for H1 2024, down 27% year-over-year due to project prioritization and lower headcount.

Outlook and guidance

• LYT-100 Phase 2b ELEVATE IPF topline results expected by end of 2024.

• FDA decision on KarXT (schizophrenia) expected by September 26, 2024; potential for milestone and royalty payments.

• Additional data from LYT-200 trials in AML, MDS, and head and neck cancers expected Q4 2024.

• Plan to select up to two new programs per year, with initial spend being minimal and program-specific.

• PureTech expects to maintain at least three years of operational runway with $330M projected cash at year-end 2024.